AmpliMed Secures $8.5 Million in Additional Series B Financing
Oncology Drug Development Company to Use Funds to Achieve Milestones in Clinical Development
By: Maureen Martino
TUCSON, Ariz.-- AmpliMed® Corporation today announced a second closing of its Series B Preferred private placement of $8.5 million, raising the total invested in the round to approximately $14.6 million. The Series B was led by Biotech Insight Ventures and included InvestBio Ventures, Valley Ventures and Solstice Capital, all of whom were previous investors. To date, AmpliMed has raised more than $24 million in financing.
External Link: http://www.fiercebiotech.com/node/4719